# TA-CIN Vaccine With Anti-PD-1 Therapy in Recurrent HPV16-associated Cancers

> **NCT05132803** · PHASE1 · WITHDRAWN · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins**

## Conditions studied

- Recurrent Human Papillomavirus Type 16 Associated Cancer

## Interventions

- **DRUG:** HPV 16 TA-CIN

## Key facts

- **NCT ID:** NCT05132803
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-08
- **Primary completion:** 2022-01-18
- **Final completion:** 2022-01-18
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study team decided not to move forward with the study.
- **Last updated:** 2022-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05132803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05132803, "TA-CIN Vaccine With Anti-PD-1 Therapy in Recurrent HPV16-associated Cancers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05132803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*